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ABSTRACT: Structure-guided drug design relies on detailed 
structural knowledge of protein-ligand complexes, but crys-
tallization of co-complexes is not always possible. Here we 
present a sensitive nuclear magnetic resonance (NMR) ap-
proach to determine the binding mode of tightly binding 
lead compounds in complex with difficult target proteins. In 
contrast to established NMR methods, it does not depend on 
rapid exchange between bound and free ligand or on stable 
isotope labeling, relying instead on a tert-butyl group as a 
chemical label. Tert-butyl groups are found in numerous 
protein ligands and deliver an exceptionally narrow and tall 
1H NMR signal. We show that a tert-butyl group also pro-
duces outstandingly intense intra- and intermolecular 
NOESY cross-peaks. These enable measurements of pseu-
docontact shifts generated by lanthanide tags attached to the 
protein, which in turn allows positioning of the ligand on the 
protein. Once the ligand has been located, assignments of 
intermolecular NOEs become possible even without prior 
resonance assignments of protein side chains. The approach 
is demonstrated with the dengue virus NS2B-NS3 protease 
in complex with a high-affinity ligand containing a tert-butyl 
group.  
Introduction 
Structure-guided ligand design is a powerful approach in 
drug discovery. Usually, the approach relies on X-ray crystal-
lography to obtain the 3D structural information of the pro-
tein-ligand complexes required to guide further ligand devel-
opment. NMR spectroscopy is often used to aid this process 
when single crystals of the protein-ligand complexes cannot 
be obtained. As the NMR resonances of ligand molecules are 
often difficult to discriminate against the background of pro-
tein NMR signals, however, NMR spectroscopic methods 
tend to perform best for weakly binding and rapidly exchang-
ing ligands that can be used in large excess over the protein.1 
In the case of tightly binding ligands, the ligand molecule 
can, for all intent and purpose, be considered to act like an 
integral part of the protein.  
The most common NMR approaches to characterize the 
complexes between proteins and tightly binding ligands in-
volve chemical shift perturbations2 and nuclear Overhauser 
effects (NOE).3 Both methods rely on the assignment of a 
large number of NMR signals. In particular, reliable assign-
ments of intermolecular NOESY cross-peaks require either 
near-complete resonance assignments of the target protein, 
which are difficult to obtain for large target proteins irrespec-
tive of the availability of 15N or 13C-labeled protein samples, 
or information from independent data, such as site-directed 
mutagenesis experiments.4 Detailed structural interpretation 
of chemical shift perturbations is difficult and requires meas-
urements with a series of ligand derivatives. 
In recent years, paramagnetic NMR methods have increas-
ingly been recruited for structural analysis of protein-ligand 
complexes, in particular by making use of paramagnetic re-
laxation enhancements (PRE) and pseudocontact shifts 
(PCS) generated by site-specifically attached tags.5 While 
much work has focused on these parameters for the analysis 
of weakly binding complexes,6-13 the ligand PCSs are exceed-
ingly small if a large excess of ligand is used. The reverse ex-
periment, generating PCSs in the target protein by attaching 
a paramagnetic metal complex to the ligand, requires a sig-
nificant chemical modification of the ligand and comprehen-
sive resonance assignments of the protein for data interpreta-
tion.14,15 Examples are rare where PCSs have been used to 
establish the structure and orientation of a tightly binding 
ligand at its binding site on the protein.6,11,16,17 The funda-
mental problem in these cases arises from the difficulty in 
identifying the resonances of the tightly bound ligand. In the 
 special situation of a protein-protein complex, isotope label-
ing allows selective observation of either protein component, 
which has been used for structure analysis of high-affinity 
protein-protein complexes using PCSs induced by paramag-
netic lanthanide ions.6,17 In the case of a small-molecule 
ligand, however, synthesis of an isotope-labeled version 
would usually be prohibitively laborious. An alternative 
strategy employs selective suppression of the 1H NMR spec-
trum of the protein by isotope labeling, either using 15N/13C-
labeling in combination with half-filter pulse sequences,18 or 
by perdeuteration of the protein.19 Either approach is imper-
fect, as the half-filters achieve only incomplete suppression of 
the protein NMR signals, due to non-uniform one-bond 
coupling constants, and are associated with significant signal 
decay by relaxation, while very high deuteration levels are 
required to reduce the residual protein 1H NMR signals to a 
level below those of the ligand. Instead of relying on costly 
isotope labeling, the present approach makes use of the 
unique NMR properties of tert-butyl groups.  
The 1H NMR signal of a tert-butyl group is an intense singlet 
with a chemical shift in the range of about 1.0 to 1.5 ppm 
depending on the chemical environment. Owing to rapid 
methyl rotation and methyl reorientation within this flexible 
group, the signal of a solvent-exposed tert-butyl group is 
much narrower than protein 1H NMR signals, enabling its 
detection even in protein complexes of high molecular mass 
without any isotope labeling.20 In experiments aimed at prob-
ing chemical exchange phenomena, we observed that the 
tert-butyl group also produces NOESY cross-peaks that are 
much more intense than anticipated and can be observed 
even under conditions where cross-peaks of the protein are 
barely detectable. This opens a new route to characterize the 
binding mode of a ligand labeled with a tert-butyl group. 
First, the NOESY cross-peaks with the tert-butyl enable 
measurements of PCSs induced by paramagnetic tags at-
tached to the protein at different sites. These data position 
the tert-butyl group with respect to the protein. If intra-
ligand NOEs with the tert-butyl group can be observed, the 
PCSs of additional ligand protons can be used to orient the 
ligand in its binding site. Finally, intermolecular NOEs with 
the tert-butyl group further pinpoint its location on the pro-
tein.  
We demonstrate the approach with the structure determina-
tion of the complex between the two-component dengue 
virus NS2B-NS3 protease (NS2B-NS3pro) from serotype 2 
(in the following referred to as DENpro) and a newly devel-
oped ligand that contains a boronic acid warhead, binds with 
high affinity, and contains a tert-butyl group (C. Nitsche and 
C. D. Klein, manuscript in preparation). Although a dengue 
vaccine has been developed that is effective against all sero-
types, the vaccine offers only incomplete protection and is 
ineffective in children below the age of 6, who need it most.21 
Dengue causes severe complications and is spreading rap-
idly,22 making DENpro a drug target of high priority.23–25 
Despite intense efforts over many years, however, crystalliza-
tion of DENpro remains difficult and only a single structure 
has been published, which proved to be of an inactive con-
formation (PDB code 2FOM).26 Co-crystal structures with 
inhibitors are available of serotype 3 (PDB code 3U1I and 
3U1J)27 and of the homologous West Nile virus protease,26 
which allow modeling of the structure of DENpro. In the 
absence of exact structural information, the development of 
high-affinity inhibitors has been slow. An effective inhibition 
constant of 43 nM was reported for the peptidic inhibitor Bz-
Nle-Lys-Arg-Arg-B(OH)2 owing to the presence of the elec-
trophilic boronic acid warhead which is thought to form a 
covalent bond to Ser135 at the active site of DENpro.28 A 
range of further inhibitors lacking a boronic acid warhead has 
been developed,25,29,30 but their binding modes remain uncer-
tain in the absence of experimental confirmation for any of 
the computational models built.   
DENpro has a molecular mass of about 27 kDa and degrades 
readily in the absence of high-affinity ligands. Its NMR spec-
trum shows broad resonances and strong signal overlap, and 
varies between different constructs and inhibitors.31-35 The 
well-resolved 15N-HSQC cross-peaks comprise about half of 
the backbone amides. We identified three single-cysteine 
mutants of DENpro for the attachment of paramagnetic lan-
thanide tags, which generate pronounced PCSs in the NMR 
spectrum of the protein.31 Using the resolved 15N-HSQC 
cross-peaks, PCS measurements are straightforward and 
allowed characterization of the conformation of DENpro in 
isolation and in complex with a small-molecule and a protein 
inhibitor, respectively.20,31 Assessing the binding mode of the 
synthetic non-protein inhibitor, however, proved intractable 
because of the difficulty in observing and assigning intermo-
lecular NOEs.  
In the following we report the binding mode of the high-
affinity ligand 1 (Figure 1) to DENpro. This is the first time 
that the complex between DENpro and a small-molecule 
ligand has been modeled at atomic resolution using experi-
mental NMR data. Importantly, the new protocol succeeded 
with a limited set of 15N-HSQC cross-peaks of backbone 
amides, which are sufficiently well resolved to enable a 
straightforward transfer of their assignments between the 
free protein and complexes with different inhibitors. 
 
Materials and Methods 
Sample preparation. Three single-cysteine mutants of 
DENpro were prepared. The mutants were Ala57*Cys (site 
A; the asterisk marks residues in NS2B), Ser34Cys (site B), 
and Ser68Cys (site C). Uniformly 15N-labeled protein sam-
ples were produced by over-expression in E. coli and selec-
tively isotope-labeled samples by cell-free synthesis as de-
scribed previously.31 The samples were ligated with C2-Ln3+ 
tags (Figure S1) as described,31,35,36 where Ln3+ is either Y3+, 
Tm3+, or Tb3+.   
 Ligands 1 and 2 were synthesized as described elsewhere (C. 
Nitsche and C. D. Klein, manuscript in preparation). 
NMR measurements. All NMR spectra were measured on a 
Bruker 800 MHz NMR spectrometer equipped with a 5 mm 
TCI cryoprobe, using 3 mm NMR tubes. 15N-HSQC spectra 
were recorded with t1max = 262 ms and t2max = 160 ms. 
NOESY spectra were recorded with a mixing time of 200 ms, 
t1max = 58 ms, and t2max = 232 ms. The total recording times of 
the NOESY spectra varied from 4 h for diamagnetic samples 
to 8 h for paramagnetic samples. 
PCSs were measured as 1H chemical shifts observed for 
DENpro tagged with C2-Tm3+ or C2-Tb3+ tags minus the 
corresponding chemical shifts measured with DENpro 
tagged with diamagnetic C2-Y3+. PCSs are through-space 
effects that follow the equation37  
 
ΔδPCS = 1/(12πr3)[Δχax(3cos2θ – 1) + 1.5Δχrh sin2θ cos2φ] 
                                                                (1) 
 
where ΔδPCS is the PCS measured in ppm, r is the distance of 
the nuclear spin from the metal ion, Δχax and Δχrh are the 
axial and rhombic components of the magnetic susceptibility 
anisotropy tensor Δχ, and θ and φ are the polar angles de-
scribing the position of the nuclear spin with respect to the 
principal axes of the Δχ tensor. We used the PCSs of back-
bone amide protons (Table S1) to fit the Δχ tensors to the 
coordinates of DENpro models generated by Rosetta.38 
PREs of the tert-butyl resonance were measured by compar-
ing its 1H NMR line widths in resolved NOESY cross-peaks 
recorded for samples tagged with paramagnetic and diamag-
netic tags. 
Modeling of the protein-ligand complex. A structural 
model of DENpro in the catalytically active conformation 
was obtained using the program Modeller39 and the crystal 
structure 3U1I27 of the protease from serotype 3 as the tem-
plate. A total of 100 models were generated following the 
advanced modeling protocol,40 and the best model was selec-
ted based on the Discrete Optimized Potential Energy 
(DOPE) score.41  
The program AutoDock-Vina42 was used to generate 20 dif-
ferent poses of the docked ligand. Each pose was checked for 
agreement with the ligand PCSs using six different Δχ ten-
sors, which had been determined from the PCSs of the back-
bone amides of DENpro with C2-Tm3+ and C2-Tb3+ tags at 
three sites. The best-fitting pose was selected for further re-
finement by the software suite Rosetta43 to model a covalent 
bond between the boron and the side chain oxygen of 
Ser135. Further restraints were introduced to ensure tetra-
hedral coordination of the boron, as detected in boronic acid 
complexes of other serine proteases such as the hepatitis C 
virus protease,44 and planarity of the guanidinum groups. 
The all-atom Relax module of Rosetta43 was used to refine 
the amino acid side chain conformations in the substrate 
binding site, following the protocol available in the protocol 
demonstrations (demos directory) of the Rosetta software 
suite.45 From the models generated by the all-atom Relax 
module, the model that best fulfilled the backbone PCSs of 
DENpro was selected as the final structure. New Δχ tensors 
were fitted to each model to find the structure with the low-
est PCS score.46  
 
Results 
1H NMR resonance of the tert-butyl group of ligand 1 in 
the absence and presence of DENpro. In the DENpro 
construct used in the present work, the linker between NS2B 
and NS3 contained the natural recognition site EVKKQR, 
leading to autoproteolytic cleavage at this site. We have 
shown previously that the resulting product assumes the 
enzymatically active closed conformation of the protease.35 
The unlinked construct degraded during NMR measure-
ments in less than a day, but was stable for months in the 
presence of ligand 1. 
The 1D 1H NMR spectrum of the free ligand shows four 
prominent resonances for the aromatic rings between 7 and 
8 ppm, and a particularly intense NMR signal for the tert-
butyl group (Figure 1). The signal of the tert-butyl group is 
also easily discernable in the 1:1 complex with DENpro, 
whereas the aromatic resonances of the ligand are difficult to 
identify even in a sample prepared with a high level of per-
deuteration of aromatic residues (Tyr, Phe, and Trp). The 
chemical shift of the tert-butyl group of ligand 1 in the bound 
state is slightly downfield compared with the chemical shift 
in the free state. In the presence of excess ligand, the signals 
of bound and free ligand were observed simultaneously, indi-
cating that any chemical exchange is slow as expected for a 
tightly bound ligand (data not shown). 
PCS measurements. The strategy of the present work relies 
on PCS measurements of the protein (to determine the Δχ 
tensors) and of the ligand (to determine the position of the 
ligand relative to the Δχ tensors and thus relative to the pro-
tein). To account for possible conformational changes 
caused by ligand binding, PCSs of DENpro were measured 
in 15N-HSQC spectra recorded of the complex between 15N-
labeled DENpro and ligand 1, using C2-Tm3+ and C2-Tb3+ 
tags at sites A-C, with C2-Y3+ tagged samples as diamagnetic 
reference (Figures S2–S4). The PCSs were very similar, but 
not identical, to PCSs measured previously for samples with-
out inhibitor35 and with the protein inhibitor BPTI.17 A total 
of 222 PCSs (Table S1) were measured and used to deter-
mine the Δχ-tensor parameters (Table S3). 
PCSs of the bound ligand 1 sometimes proved difficult to 
determine from simple 1D 1H NMR spectra. The intense 1H 
NMR resonance of the tert-butyl group was readily detected 
in the diamagnetic samples, but PREs combined with chang-
es in the NMR spectrum of the protein can make it difficult 
 difficult to identify the resonance in the paramagnetically 
tagged samples (Figure S5).   
 
Figure 1. 1D 1H NMR spectra of ligand 1 without and with 
DENpro. (A) Chemical structure of ligand 1. Ligand 2 is struc-
turally identical except for the absence of the tert-butyl group. 
(B) 1D 1H NMR spectrum of ligand 1 in the absence of DEN-
pro. The spectrum was recorded at 25 oC in NMR buffer (20 
mM MES, pH 6.5, 50 mM NaCl) using a 800 MHz NMR spec-
trometer. The downfield region of the spectrum was scaled up 
8-fold relative to the upfield part of the spectrum. The open 
arrow marks the 1H NMR resonance of the tert-butyl group. 
The star identifies the signal from an impurity. (C) 1D 1H NMR 
spectra of 50 µM solutions of DENpro in deuterated NMR 
buffer without ligand (bottom trace) and in a 1:1 complex with 
ligand 1 (top trace). The spectral appearance of the aromatic 
region was simplified by perdeuteration of Tyr, Phe, and Trp. 
Signals at 7.3 and 8.0 ppm are from the C-terminal His6-tag. 
The low-field region was scaled up 2-fold relative to the high-
field region. The resonance of the tert-butyl group of ligand 1 is 
marked by a filled arrow. The star identifies the signal of a non-
binding impurity.  
 
In contrast, NOESY spectra turned out to yield intense 
cross-peaks with the tert-butyl resonance that could easily be 
followed even when the tert-butyl resonance was broadened 
by PRE. In addition, the NOESY spectra yield PCSs not only 
for the tert-butyl resonance itself but also for the protons 
involved in the NOEs with the tert-butyl group. Figure 2B 
illustrates the intensity of the tert-butyl cross-peaks with the 
wild-type protein. The cross-peaks are readily identified by 
their narrow lineshape in the detection dimension. As ex-
pected, they were absent from the corresponding NOESY 
spectrum recorded with ligand 2, which is the same as ligand 
1 but without the tert-butyl group (Figure 2A). Particularly 
intense cross-peaks are observed with protons at about 7.5 
ppm, which were assigned to the aromatic ligand protons in 
the positions ortho and meta to the tert-butyl group labeled 1, 
1’, 2, and 2’ in Figure 1A. (Using a sample prepared with 15N-
labeled DENpro, a NOESY spectrum recorded without 15N-
decoupling confirmed that these NOEs are not with amide 
protons.) Additional cross-peaks at about 0.7 and 1.7 ppm 
cannot be explained as intra-ligand NOEs and, based on the 
chemical shifts, include NOEs with methyl groups. 
 
 
Figure 2. NOESY spectra of DENpro in complex with ligands 1 
and 2. The spectra were recorded at 25 oC of 150 µM solutions 
of unlabeled wild-type DENpro in NMR buffer containing 10% 
D2O, using 3 mm NMR tubes in a 5 mm TCI cryoprobe. Ex-
perimental parameters: 200 ms mixing time, t1max = 58 ms, t2max = 
232 ms, total recording time per spectrum 4 h. The spectral 
region shown captures the NOE cross-peaks of the tert-butyl 
resonance. (A) NOESY spectrum of the complex with ligand 2. 
(B) NOESY spectrum of the complex with ligand 1. Five cross-
peaks with the tert-butyl resonance are labeled. Note that these 
cross-peaks were readily detected, while other cross-peaks, e.g. 
with amide protons, were much weaker or unobservable.  
Figure 3 illustrates the measurement of PCSs from the 
NOESY cross-peaks with the tert-butyl resonance. The cross-
peaks were preserved between wild-type DENpro and DEN-
 pro tagged with diamagnetic C2-Y3+ tags, and were displaced 
by PCSs in the samples containing paramagnetic tags. Dif-
ferent to backbone amides, where PCSs displace 15N-HSQC 
cross-peaks along mostly parallel lines owing to the close 
spatial proximity of 1H and 15N spins, the PCSs observed for 
the protons involved in NOEs with the tert-butyl resonance 
were mostly different from the PCS of the tert-butyl reso-
nance itself, as expected for spins that are located at more 
disparate positions relative to the Δχ tensors of the paramag-
netic tags. Importantly, the C2-Tm3+ and C2-Tb3+ tags pro-
duced PCSs of opposite sign31,36 and the NOESY cross-peaks 
of the three samples tagged with C2-Tm3+, C2-Y3+, and C2-
Tb3+ tags could be connected by almost straight lines. This 
greatly aids the identification of the paramagnetically shifted 
cross-peaks, even when the cross-peaks were significantly 
broadened by PREs, as for the paramagnetic samples tagged 
at site B (Figure 3B). 
Altogether, the NOESY cross-peaks observed with the tert-
butyl resonance delivered 18 ligand PCSs together with 14 
protein PCSs (Table S2). The ligand PCSs immediately en-
able a qualitative structural interpretation regarding the ori-
entation of the tert-butylphenyl group relative to the Δχ ten-
sors. For example, the PCSs obtained with the tags at site B 
decrease in magnitude in moving from the protons at posi-
tions 2/2’ to those at positions 1/1’ to the tert-butyl group 
(Figure 3B), suggesting that the tert-butyl group faces away 
from the tag at site B. This conclusion is confirmed by the 
broad line widths of cross-peaks observed for the H-2/2’ 
resonances in the paramagnetic samples, particularly for 
DENpro tagged at site B, which can be attributed to PREs 
due to proximity to the tag.  
PRE measurement. As the tert-butyl resonance is a singlet, 
PREs can simply be measured as the difference in line width 
observed in paramagnetic and diamagnetic samples. The 
NOESY cross-peaks of Figure 3 clearly show that the tert-
butyl resonance is broader in the samples with paramagnetic 
versus diamagnetic tags, and broader with Tb3+ tags than with 
Tm3+ tags, as expected from the greater paramagnetic mo-
ment of Tb3+.47 It is difficult, however, to convert the PREs 
into quantitative distance restraints from the metal ions. First, 
the significant anisotropy of the magnetic susceptibility ten-
sors associated with Tb3+ and Tm3+ needs to be taken into 
account.48 Second, the PREs can be compromised by cross-
correlation effects with nuclear chemical shift anisotropies.49 
Most importantly, however, the linker of the C2 tag is not 
entirely rigid, resulting in multiple possible metal positions. 
For a conservative estimate of the distance restraint indi-
cated by a PRE, we calculated the largest distance compatible 
with the Δχ tensor anisotropies determined from the PCSs 
using the anisotropic Curie-spin relaxation equations44 with a 
rotational correlation time of 10 ns. We only used the data 
from site B, which showed the greatest PRE effects (Figure 
3). In this construct, the C2-Tb3+ and C2-Tm3+ tags broad-
ened the tert-butyl signal by 22 and 13 Hz, respectively, rela-
tive to the diamagnetic sample with the C2-Y3+ tag. Both 
measurements correspond to a distance from the paramag-
netic center of about 15.5 Å. To account for the uncertainty 
in metal position, we converted the PREs observed for mu-
tant B into an upper distance restraint of 20 Å.  
 
Figure 3. PCSs observed in 2D NOESY spectra of DENpro 
with C2 tags at three different sites. The spectra were recorded 
of 150 µM solutions of 15N-labeled DENpro complexes with 
ligand 1 in NMR buffer at 25 oC. The figure shows superimposi-
tions of NOESY spectra for samples tagged with C2-Y3+ (black), 
C2-Tm3+ (blue) and C2-Tb3+ (red). The spectral regions shown 
contain cross-peaks between the tert-butyl resonance and pro-
tons in the aromatic and methyl regions of the NMR spectrum. 
PCSs are identified by lines drawn between cross-peaks of the 
diamagnetic samples and their corresponding peaks in the par-
amagnetic samples. (A) NOESY spectra of the complex tagged 
at site A. (B) Same as (A), but for the complex tagged at site B. 
(C) Same as (A), but for the complex tagged at site C. NOEs 
with two unassigned methyl groups are labeled as CH3-1 and 
CH3-2. The NOEs with two aromatic protons were attributed 
to the protons 1/1’ and 2/2’ of the ligand (Figure 1A).  
 
PCS-guided modeling of the protein-ligand complex. As 
no crystal structure of DENpro in the active conformation is 
available and the amino acid sequences of NS2B-NS3pro of 
serotypes 2 and 3 are 66% sequence identical, we modeled 
the structure of DENpro on the crystal structure 3U1I of 
serotype 3.27 Among 100 very similar homology models, we 
selected the best model based on the DOPE score,41 which 
had a Cα-RMSD of 0.7 Å relative to the crystal structure 
3U1I.   
 The Δχ tensors associated with the C2-Tm3+ and C2-Tb3+ 
tags at sites A-C produce different PCSs at different sites of 
the DENpro-ligand complex. Using the Δχ tensors deter-
mined for the best-fitting model of DENpro, we predicted 
the PCSs for every point of a dense grid placed over the 
structural model of DENpro to identify all the points that 
were in agreement with the PCSs generated by the C2-Tm3+ 
and C2-Tb3+ tags at sites A-C.  
Allowing for an uncertainty range of ±0.02 ppm for the ex-
perimental PCSs, the PCSs of the tert-butyl group of the 
ligand identified a continuous space in the vicinity of NS2B, 
where the tert-butyl group could be located. We refer to this 
PCS-supported grid point volume as localization space. The 
localization space of the tert-butyl group was in full agree-
ment with its expected position upon formation of a covalent 
bond between Ser135 and the boronic acid moiety of the 
ligand, as anticipated in the design of the ligand. The local-
ization space shown in Figure 4 was further restricted by 
imposing the 20 Å distance restraint from the metal position 
of the tag at site B, which had been derived from PREs.  
To generate a complete model of the ligand, 20 poses of lig-
and 1 were generated on the structural model of DENpro 
using the program AutoDock-Vina.42 The different poses 
produced dramatically different ligand structures and orien-
tations (with a pairwise RMSD of about 10 Å) with very 
similar calculated binding energies (ranging from -7.5 to -7.9 
kcal/mol). The two top-ranked and seven further poses ap-
proximately positioned the tert-butyl group in the localiza-
tion space defined by the PCSs. Furthermore, the top-ranked 
pose positioned the boronic acid group in the vicinity of 
Ser135 and the direction of the tert-butylphenyl group was 
also in general agreement with the localization spaces of the 
1/1’ and 2/2’ protons (Figure 4). To refine this model of the 
protein-ligand complex, we used the Rosetta software 
suite38,43 to form a covalent bond between the boron of the 
ligand and the side chain oxygen of Ser135, and allowed 
small structural adjustments by the all-atom ‘Relax’ refine-
ment protocol of Rosetta. The protocol generated 1000 
structures of the complex, all with conserved protein con-
formations and similar ligand conformations (over 90% 
within 1.3 Å of the structure with the lowest PCS energy, 
Figure S6). The protein structure with the lowest PCS score 
showed an excellent correlation between the experimental 
and back-calculated PCSs (Figure S7). Figure 4 shows the 
structure best fulfilling the PCSs of DENpro, which was cho-
sen as the final representation of the DENpro-ligand 1 com-
plex.  
The localization spaces of protons 1/1’ and 2/2’ (Figure 4) 
are progressively closer to the site B, reflecting the large 
PCSs induced by C2 tags at this site (Figure 3B). This pro-
vides strong support for the orientation of the tert-butyl 
phenyl group. The apparent discrepancies between experi-
mental localization spaces and actual proton positions in the 
model of Figure 4 may arise from mobility of the tag at site B, 
which can increase the PCSs by transiently shortening the 
distance between metal and ligand. As PCSs present long-
range restraints, experimental uncertainties translate into 
relatively large uncertainties for localization spaces. There-
fore, we used the intermolecular NOEs observed with the 
tert-butyl group to verify the correctness of the model of the 
complex. 
 
 
 
Figure 4. Model of the complex between DENpro and ligand 1. 
NS2B (orange) and NS3pro (grey) are drawn in a cartoon rep-
resentation, and ligand 1 is shown in a stick representation, dis-
playing hydrogens only for amide and guanidinium groups. 
Green balls indicate the positions of the lanthanide ions as de-
termined by PCSs for the tags at sites A-C. Meshes identify the 
localization spaces of the tert-butyl group (magenta), protons 
1/1’ (purple), and protons 2/2’ (cyan) identified by PCSs from 
C2-Tm3+ and C2-Tb3+ tags at sites A-C. The meshes capture 
localization spaces with PCS deviations smaller than 0.02 ppm 
from the experimental PCSs.  
Verification of the structural model by intermolecular 
NOEs. The model of the complex between DENpro and 
ligand 1 predicts intermolecular NOEs between the tert-
butyl group and the methyl groups of Val154 and Val155. 
The chemical shifts of the NOEs observed with the signals of 
CH3-1 and CH3-2 (Figure 3) agree with expectations for 
valine methyl groups.  
To support this assignment, we recorded a NOESY spec-
trum of the DENpro-ligand 1 complex in which wild-type 
DENpro was selectively labeled with 13C-valine. In the ab-
sence of 13C decoupling, the NOESY cross-peaks labeled 1 
and 2 in Figure 2 split by 1JCH coupling constants and the 
signal of 3 could no longer be resolved, showing that all three 
protons indeed belong to valine (Figure S8). To distinguish 
between Val154 and Val155, we measured a NOESY spec-
trum of the mutant Val155Ile selectively labeled with 13C-
valine. The NOESY cross-peaks observed were in agreement 
with an isoleucine residue and did not split in the absence of 
13C-decoupling, indicating that the NOEs between the tert-
 butyl group of ligand 1 and wild-type DENpro are with 
Val155 (Figure S9). 
 
Discussion 
The surprisingly high signal-to-noise ratio of NOESY cross-
peaks with a tert-butyl group can be attributed to three fac-
tors. Most importantly, its 1H NMR resonance is intrinsically 
narrow because of short effective rotational correlation times 
arising from fast methyl group rotation and rotation of the 
tert-butyl group. Second, the signal stands out because it 
corresponds to nine protons. Finally, in view of the very 
strong distance dependence of NOEs, a small population of a 
short 1H-1H distance can lead to a stronger NOE than a lar-
ger population of a slightly longer 1H-1H distance. Therefore, 
motions of the tert-butyl group that transiently shorten the 
1H-1H distance can strongly enhance the overall NOE. In 
this way, NOEs can be observed for proteins of increased 
molecular weight, which usually display broad 1H NMR lines. 
In fact, the broad widths of the protein resonances are an 
advantage in our approach, as this decreases the background 
of NOESY cross-peaks between other protons. The high 
sensitivity of the NOESY cross-peaks with the tert-butyl 
resonance enabled their detection in a few hours, using about 
100 µM solutions of the complex in 3 mm NMR tubes.  
The attempt to use the prominence of the tert-butyl reso-
nance in 1D 1H NMR spectra for PCS measurements was 
compromised by too many spectral changes caused by the 
paramagnetic tags, including a much broader tert-butyl reso-
nance (Figure S5). In contrast, the line-up of NOESY cross-
peaks with the same tert-butyl signal delivered safe assign-
ments of its PCSs. It is an advantage of the NOESY spectrum 
that different cross-peaks have different intensities, as this 
can be used to track the cross-peaks in the paramagnetic 
samples, as in the example of the aromatic peaks in Figure 3B. 
This makes the assignment of PCSs easier in 2D NOESY 
spectra than in 2D 15N-HSQC spectra.  
It is an important additional benefit that NOESY cross-peaks 
also deliver the PCSs of the interacting proton spins. While 
the PCSs of a 15N-1H group tend to be very similar for the 
15N and 1H spins due to their close spatial proximity, the 1H 
spins involved in a NOE are further apart and thus more like-
ly to display PCSs of different magnitude. This presents 
highly useful information for orienting the inter-nuclear vec-
tor relative to the Δχ tensor. In the case of the tert-butyl 
phenyl group of ligand 1, PCSs were available from three 
different tagging sites, which unambiguously determined its 
orientation relative to the protein.  
As is common with drug targets of moderate complexity, 
resonance assignments of DENpro could be obtained with 
reasonable effort for spectrally resolved 15N-HSQC cross-
peaks, whereas near-complete resonance assignments, as 
required for conventional NOESY cross-peak assignments, 
would be prohibitively laborious to establish for every com-
plex with a new ligand. In this situation, PCSs present a 
much more efficient route to structural information, as Δχ 
tensors can be determined from PCSs of a small number of 
resolved backbone amide peaks, which can be assigned by, 
e.g., systematic site-directed mutagenesis of selectively iso-
tope-labeled samples.50,51 While the accuracy of PCSs may be 
insufficient to predict close intermolecular protein-ligand 
contacts, the localization spaces defined by PCSs from par-
amagnetic tags at multiple sites greatly limit the number of 
possible assignments for intermolecular NOEs observed with 
the tert-butyl resonance. As shown in the present work, the 
residue type of the protein protons involved in the intermo-
lecular NOEs can be ascertained by chemical shifts as well as 
selective isotope labeling.  
In many instances, it is easier to synthesize a ligand molecule 
with a tert-butyl group than with a stable isotope, in particu-
lar as tert-butyl groups are part of common synthetic building 
blocks and protection strategies. Consequently, tert-butyl 
groups are also frequently found in fragment libraries and 
series of inhibitor candidates during the early phases of the 
drug discovery process. The tert-butyl moiety can establish 
hydrophobic protein-ligand interactions and therefore often 
increases ligand affinity. It is also present in recently ap-
proved drugs, such as the HCV protease inhibitors bocepre-
vir and telaprevir.52 If a tert-butyl group is highly solvent 
exposed and flexible, it will produce less intense NOEs, but 
its 1H NMR signal will be narrower, which facilitates 
identification of its localization space as a taller signal makes 
it easier to extract PCSs from 1D NMR spectra.   
Ligands containing fluorine have found widespread applica-
tion as NMR probes for protein-ligand studies.16,53 In princi-
ple, the combined PCS and NOE strategy outlined in the 
present work could be extended to 1H-19F HOESY spectra, 
except that sensitivity would be compromised by the much 
broader line width of 19F combined with typically fewer 19F 
spins in the ligand molecules.  
In conclusion, the combined PCS and NOE approach of the 
present work opens a practical and expedient route to eluci-
date the binding mode of high-affinity ligands in 1:1 com-
plexes of protein targets. In contrast to studies with weakly 
binding ligands, no excess of ligand is required, which is an 
important advantage in the case of poorly soluble com-
pounds. Detailed structural information about the protein-
ligand complex can be obtained without costly perdeuter-
ation, and dilute solutions of protein-ligand complexes with 
highly incomplete NMR resonance assignments can be in-
vestigated. While multiple samples with different paramag-
netic tags are required to measure the PCSs and NOEs, each 
NMR experiment is quick and uses protein sparingly, making 
it practical to study a protein with a set of different ligands. 
The structural data that can be obtained with this strategy 
open a new and unique window of opportunity for the ra-
tional development of high-affinity lead compounds in drug 
development projects, when co-crystal structures of the pro-
 tein-ligand complex cannot be obtained with acceptable ef-
fort.  
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Table S1. PCSs measured of backbone amide protons of DENpro in complex with ligand 1.a 
Residue Site A  Site B  Site C 
Tm3+ 
(ppm) 
Tb3+ 
(ppm) 
 Tm3+ 
(ppm) 
Tb3+ 
(ppm) 
 Tm3+ 
(ppm) 
Tb3+ 
(ppm) NS2B         
Ser70* -0.35  0.46  -0.06  0.08  -0.01  0 
Ser71* -0.26  0.33  -0.05  0.06  -0.02  0.02 
Ile73* - -  -0.05  0.07  -0.08  0.09 
Leu74* -0.12  0.18  -0.06  0.09  -0.05  0.08 
Ser75*  -0.09  0.11  -0.06  0.08  -0.06  0.09 
Ile78* -0.07 -  -0.11  0.17  -0.09  0.20 
Ser79* -0.01  0.02  -0.21  0.25  -0.23  0.34 
Asp81* - -  -  0.33  -0.34 -0.54 
Gly82*  - -  -0.26  0.33  -0.37  0.58 
Ser83* - -  -0.34  0.42  -0.31  0.48 
Ser85* -0.03  0.05  -0.16  0.20  -0.14  0.21 
Ile86*  -0.05 -  -0.11  0.12  -0.09  0.14 
Lys87* -0.05  0.08  -0.07  0.08  -0.08  0.11 
NS3pro         
Gly21  0.58 -   0.16 -0.19  - - 
Ala22 - -   0.18 -0.22  - - 
Tyr23 - -   0.32 -0.38  - - 
Lys28 - -  - -   0.31 -0.53 
Ser34 - -  - -   0.21 - 
 S3 
Gly39  0.83 -0.99   0.37 -0.44   0.49 -0.76 
Tyr41  0.59 -0.72   0.20 -0.23   0.56 -0.84 
Lys42  0.20 -0.25   0.15 -0.17  - - 
Glu43  0.04 -0.06   0.10 -0.12  - - 
Gly44  0.14 -0.19   0.12 -0.16  - - 
Phe46  0.26 -0.30   0.20 -0.23  - - 
Trp50  0.10 -0.12  - -  - - 
His51  0.12 -0.14  - -  -0.32  0.05 
Val52  0.19 -0.23  - -  -0.03 - 
Thr53  0.24 -0.29  - -   0.14 -0.26 
Gly55  0.19 -0.23  - -  - - 
Gly62  0.47 -0.58   0.38 -0.44  - -1.26 
Glu66  0.23 -   0.24 -  - - 
Ala70  0.05 -0.05  -0.05  0.05  - - 
Ser78 - -   0.06 -0.07  - - 
Gly81  0.14 -0.15   0.12 -0.16  - - 
Gly82  0.05 -0.06   0.07 -0.08  - - 
Leu85 -  0.10   0.05 -0.04  - - 
Trp89 - -  -0.03  0.03  -0.06  0.08 
Gly92 -0.28  0.37  - -  -0.03  0.04 
Gln96 - -  - -   0.04 -0.07 
Leu98 -1.15 -  - -   0.10 -0.17 
Leu100 - -  - -   0.17 -0.26 
 S4 
Gly103 - -  - -   0.16 -0.26 
Gln110 - -  -0.03  0.05   0.03 -0.06 
Thr111 -  1.18  -0.04  0.06  - - 
Gly114 -0.28 -  -0.08  0.08  - - 
Phe116 -0.15  0.21  -0.09  0.10  -0.08  0.11 
Lys117 - -  -0.08  0.09  -0.07  0.11 
Thr120 -0.06  0.08  -0.07  0.09  -0.12  0.19 
Gly121 -0.07  0.10  -0.06  0.08  -0.11  0.15 
Thr122 - -  -0.05  0.07  -0.10  0.14 
Ile123 - -  - -  -0.12  0.11 
Ser127 -0.36 -  -0.09  0.11  - - 
Val140 - -  - -   0.06 -0.10 
Gly148 -0.38  0.49  - -   0.02 -0.06 
Ala160 -0.11  0.15  -0.04  0.05  -0.03  0.05 
Ala164 - -  -0.22  0.28  -0.08  0.12 
Ile165 - -  -0.12  0.14  - - 
Ala166 - -  -0.08 -  -0.08  0.13 
 
a PCSs were generated by C2-Tm3+ and C2-Tb3+ tags at sites A-C. Corresponding samples with 
C2-Y3+ tags were used as the diamagnetic reference. PCSs are reported in ppm as the 1H 
chemical shift measured in the presence of paramagnetic tag minus the 1H chemical shift 
measured of the diamagnetic reference. 
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Table S2. PCSs observed in NOESY spectra of the complex between ligand 1 and DENpro with 
C2-Ln3+ tagsa 
 Ligand 1  Protein 
Tag site and 
metal 
tert-butyl 
group 
(ppm) 
H-1/1’ 
(ppm) 
H-2/2’  
(ppm) 
 
CH3-1 
 (ppm) 
CH3-2 
(ppm) 
H-3 
(ppm) 
A-Tm3+ -0.01  0.00  0.00  -0.05 -0.06 -0.05 
A-Tb3+  0.02  0.01  0.01   0.07  0.09  0.08 
B-Tm3+ -0.09 -0.27 -0.56  -0.14 n.d. n.d. 
B-Tb3+ 0.10  0.33  0.67   0.15 n.d. n.d. 
C-Tm3+ -0.10 -0.10 -0.10  -0.06 -0.05 -0.06 
C-Tb3+  0.16  0.16  0.16   0.09  0.07  0.10 
Chemical 
shifta 
 1.30  7.54  7.66   0.67  0.78  1.73 
 
a Measured for the complex of ligand 1 with wild-type DENpro without tag. See Figures 1A and 
2B for the numbering of the proton resonances. n.d., not detected. 
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Table S3. Δχ tensor parameters fitted to the homology model built of DENpro and refined by 
Rosettaa 
Tagging site and 
metal 
Δχax Δχrh x y z α β γ 
A-Tm3+  17.1  6.7 16.415 -18.172 36.099 140.1 139.5 38.5 
A-Tb3+ -21.1 -8.3 16.415 -18.172 36.099 141.4 139.8 42.7 
B-Tm3+    8.7  2.0   8.634 -21.149  7.976 102.9   54.8 43.0 
B-Tb3+ -10.5 -2.7   8.634 -21.149  7.976 102.5   56.8 41.8 
C-Tm3+  17.7  3.5 13.935    4.362  4.462   49.3 147.9 82.2 
C-Tb3+ -27.4 -6.9 13.935    4.362  4.462   49.3 147.9 82.2 
 
a The tensor parameters are reported with respect to the final Rosetta-refined model, which is 
available from http://rsc.anu.edu.au/~go/coordinates/. The axial and rhombic components of the 
Δχ tensors are given in 10-32 m3 and the Euler angles in degrees, using the zyz convention and 
unique tensor representation.1 Δχ tensor fits were performed by restricting Tb3+ and Tm3+ to the 
same site. 
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Figure S1. Chemical structure of the C2-Ln3+ tag.2 
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Figure S2. 15N-HSQC spectra of DENpro without (left spectrum) and with ligand 1 (right 
spectrum). The spectra were recorded of 150 µM solutions of uniformly 15N-labeled DENpro 
tagged at site B with a diamagnetic C2-Y3+ tag. The comparison shows that many of the well-
resolved peaks can be tracked despite some changes in chemical shifts.   
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Figure S3. 15N-HSQC spectrum recorded of a 150 µM solution of uniformly 15N-labeled 
DENpro tagged at site A with a diamagnetic C2-Y3+ tag and in complex with ligand 1. Solution 
conditions: 20 mM MES, pH 6.5, 50 mM NaCl, 25 oC. The spectrum was recorded using a 3 mm 
NMR tube on a Bruker 800 MHz NMR spectrometer equipped with a TCI cryoprobe. The cross-
peaks used as diamagnetic reference for PCS measurements (Table S1) are marked with their 
sequence-specific residue assignments. 
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Figure S4. PCS measurements of backbone amide protons. The figure shows superimpositions 
of 15N-HSQC spectra recorded of uniformly 15N-labeled DENpro in complex with ligand 1 with 
 S11 
C2-Ln3+ tags at different sites of DENpro. Panels A-C show the spectra with tags at sites A, B, 
and C, respectively. Spectra of DENpro with diamagnetic tag (C2-Y3+) are shown in black, and 
the corresponding spectra with paramagnetic tags are plotted in red (C2-Tm3+) and blue (C2-
Tb3+). Selected cross-peaks are linked by lines indicating the pseudocontact shifts. The spectra 
were recorded of 150 µM solutions of DENpro-ligand 1 complexes in NMR buffer (pH 6.5) at 
25 oC, using a Bruker 800 MHz NMR spectrometer. Based on the cross-peaks observed in these 
15N-HSQC spectra, the tag ligation yields at sites A-C were about 80%, 70%, and 90%, 
respectively.  
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Figure S5. PCSs of the tert-butyl signal observed in 1D 1H NMR spectra measured of ligand 1 in 
complex with DENpro with different C2-Ln3+ tags loaded with different metal ions as indicated. 
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The panels A-C show the data obtained with C2-Ln3+ tags at sites A, B, and C, respectively. The 
spectra were recorded of ca. 150 µM solutions of uniformly 15N labeled DENpro samples in 
NMR buffer containing 10% D2O at 25 oC. Each panel contains three groups of three spectra, 
where each group shows the result of titration of the tagged protein with increasing amounts of 
ligand 1 from bottom to top in stoichiometric ratios as indicated. The dashed line identifies the 
chemical shift of the tert-butyl signal of the bound ligand in the diamagnetic samples. This 
chemical shift is independent of the site of the diamagnetic tag and the same as in wild-type 
protein. Signals from a non-binding impurity in the ligand stock are labeled with a star. Filled 
rhombuses and triangles mark the chemical shifts of the tert-butyl group in samples tagged with 
C2-Tm3+ and C2-Tb3+, respectively. Note the increase of the tert-butyl resonance of bound 
ligand 1 with increasing ligand concentrations, but also that the tert-butyl resonance is difficult 
to assign in panels A and B due to spectral changes induced in the protein NMR spectrum upon 
ligand binding as well as PREs associated with paramagnetic metal ions.  
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Figure S6. PCS energies and RMSDs of the ligand poses after all-atom Rosetta refinement. (A) 
PCS energy of the protein (in Rosetta energy units) vs RMSD of the ligand to the final pose 
(highlighted in red). 1000 structures were produced by the Rosetta refinement protocol, which 
were all very similar and showed very similar PCS energies. The final ligand pose and protein 
structure was chosen as the protein-ligand complex with the lowest PCS energy of the protein. 
The RMSD was calculated for heavy atoms of the ligand only. All ligand poses were within 2.5 
Å from the best pose. (B) Probability density plot of the ligand RMSDs with respect to the final 
docked pose of the ligand. The vertical bar shows that about 92% of the ligand poses are within 
1.3 Å from the best pose. 
 
 
 
Figure S7. Correlation between experimental and back-calculated PCSs fitted on the model 
structure. The data from C2-Tm3+ and C2-Tb3+ tags are shown as red and black points, 
respectively. (A)-(C) are the correlation plots drawn for the three different mutants A, B, and C, 
respectively. The Δχ tensor parameters are reported in Table S3. 
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Figure S8. Selected spectral region of NOESY spectra of DENpro in complex with ligand 1, 
showing cross-peaks between the methyl groups of Val and the tert-butyl resonance of the 
ligand. The left-most panel shows the spectrum recorded with ligand 2, which is devoid of a tert-
butyl group. The center and right panels show the spectra of complexes of ligand 1 with 
unlabeled DENpro and DENpro prepared with 13C/15N-labeled valine, respectively. The cross-
peaks are clearly split by 1JCH couplings in the spectrum with isotope-labeled valine. The 
chemical shifts of the cross-peaks in the indirect dimensions identify the cross-peaks as NOEs 
with methyl groups of valine. 
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Figure S9. Assignment of NOEs between methyl groups of protein side chains and the tert-butyl 
group of ligand 1. Right panel: zoom into the spectral region from the NOESY spectrum shown 
in Figure 2B of the main text. Cross-peaks with the tert-butyl resonance of ligand 1 are 
numbered as in Figure 2B. Left panel: same as the right panel, except for the complex of ligand 1 
with the mutant Val155Ile of DENpro rather than wild-type DENpro. Note that the cross-peaks 
of the Val155Ile mutant display no splitting by 1JHC couplings, although the protein had been 
prepared with 13C-labeled valine and the spectrum was recorded without 13C-decoupling. This 
result indicates that the cross-peaks 1–3 in wild-type DENpro are with Val155 rather than 
Val154, and that the corresponding cross-peaks observed in the Val155Ile mutant are with 
isoleucine. The localization space of the tert-butyl group shown in Figure 4 of the main text is 
not near any other methyl group of DENpro. Also note that all NOESY cross-peaks with the tert-
butyl group are slightly shifted because of a small change in its chemical shift, providing an 
independent means of identification beyond their narrow line width in the detection dimension. 
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Figure S10.	 Stereo view comparing the crystal structure of serotype 3 with peptide inhibitor 
(PDB code 3U1I),3 and the Rosetta-refined model structure of DENpro in complex with ligand 1 
determined in the present work. The Rosetta all-atom refinement adjusted the conformation of 
the backbone atoms around the ligand binding site both for NS2B and NS3pro. NS2B and 
NS3pro of the crystal structure are shown in blue and red, respectively, with the peptide ligand 
shown in a stick representation with a cyan backbone. NS2B and NS3pro of the model are shown 
in orange and grey, with ligand 1 in a stick representation with green backbone atoms. Nitrogen 
and oxygen atoms are shown in dark blue and red, respectively. Yellow balls mark the sites A-C 
mutated to cysteine for attachment of C2-Ln3+ tags. The backbone of ligand 1 closely aligns with 
the backbone of the peptide ligand in the crystal structure. The Rosetta all-atom refinement 
resulted in a small shift of the C-terminal two-stranded β-sheet of NS3pro (residues 154-164) 
and of the C-terminal β-strand of NS2B (residues 73*-83*) towards the ligand. 
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